Exelixis Inc. EXEL
Super Investor & Insider
1
Fondi che lo detengono
#1440
Rank consenso
1.4%
% dei portafogli
$428,900
Valore detenuto
| Fondo | % portaf. | Attività | Azioni | Valore |
|---|---|---|---|---|
| First Eagle Investment Management · First Eagle Investment Management | 0% | Reduce 20.45% | 10,000 | $428,900 |
Fondi: 13F-HR alla SEC. Insider: acquisti (P) e vendite (S) in borsa da SEC EDGAR, ultimi 12 mesi.
About
Exelixis Inc. is an oncology-focused biotechnology company dedicated to the discovery, development, and commercialization of new medicines for difficult-to-treat cancers. Its lead product, CABOMETYX tablets (cabozantinib), treats advanced renal cell carcinoma in patients following prior anti-angiogenic therapy and supp…
SectorHealthcare
ExchangeNASDAQ
IndustryBiotechnology
CountryUnited States
Employees1,077
TickerEXEL
Statistics
Market Cap$13.33B
Revenue (TTM)$2.32B
Net Income$782.6M
Net Margin33.7%
EPS$2.78
P/E17.72
P/S5.66
P/B7.01
EV/EBITDA12.79
ROE41.0%
Dividend Yield—
Price$52.56
Data: Twelve Data · Revenue = mcap / P/S